Current treatment options for early HER2-positive breast cancer
MUDr. Miloš Holánek
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
Anti-HER2 therapy has long been an integral part of the treatment of patients with HER2-positive breast cancer, which has significantly improved treatment outcomes and disease prognosis. However, despite effective therapy, some patients still relapse. Therefore, other possibilities are being sought to further improve the already very effective therapy.
anti-HER2 therapy, trastuzumab, pertuzumab, trastuzumab emtansine, neratinib
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...